Clinical Trial Update: UB-312 in Patients With Synucleinopathies [Phase 1]

View source ↗

Summary

Phase 1 trial of UB-312 in synucleinopathies (Parkinson's disease and Multiple System Atrophy) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Parkinson Disease

Drugs mentioned

• UB-312

Snippet

Sponsor: NYU Langone Health | Conditions: Multiple System Atrophy, Parkinson Disease | Phase 1 | Status: COMPLETED